<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02481323</url>
  </required_header>
  <id_info>
    <org_study_id>PrevSVD-2015</org_study_id>
    <secondary_id>2015-001953-33</secondary_id>
    <secondary_id>252 (AS-PG-14-033)</secondary_id>
    <nct_id>NCT02481323</nct_id>
  </id_info>
  <brief_title>Lacunar Intervention Trial 1 (LACI-1)</brief_title>
  <acronym>Prevent-SVD</acronym>
  <official_title>Preventing Cognitive Decline and Dementia From Cerebral Small Vessel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II pilot randomised, factorial, short term dose escalation, open label, blinded&#xD;
      intermediary endpoint trial, in two hospital centres in the UK, of tolerability and safety of&#xD;
      cilostazol, isosorbide mononitrate, both or neither in patients with small vessel disease&#xD;
      manifest as symptomatic small subcortical stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A quarter of all ischaemic strokes are lacunar (small vessel) in type, about 35000 per annum&#xD;
      in the United Kingdom, and due to an intrinsic, non-atheromatous, non-cardioembolic&#xD;
      perforating cerebral arteriolar disease. 'Small vessel disease' also affects the brain&#xD;
      diffusely, causing up to 40% of dementias, alone or mixed with Alzheimer's disease, 350,000+&#xD;
      patients estimated currently in the United Kingdom. There is no proven treatment:&#xD;
      conventional antiplatelet drugs may be ineffective or even hazardous, antihypertensive&#xD;
      treatment and statins have been disappointing. The disease mechanism is poorly understood but&#xD;
      endothelial dysfunction, blood-brain barrier failure and vessel stiffness appear to&#xD;
      contribute to the pathogenesis. Promising data available for licensed drugs with relevant&#xD;
      modes of action, cilostazol (&gt;6000 stroke patients in the Asia Pacific region) and isosorbide&#xD;
      mononitrate (ISMN, widely used in cardiac disease) support their testing in small vessel&#xD;
      disease. This trial will be a phase 2, randomised, dose-escalation, factorial trial to test&#xD;
      short-term administration of cilostazol, Isosorbide Mononitrate, both, or neither, to provide&#xD;
      data on patient tolerability of dose (including headache, dizziness), safety (including blood&#xD;
      pressure, platelet function), provide mechanistic evidence of efficacy (cerebrovascular&#xD;
      reactivity, arterial compliance), and to inform the design of a larger phase 2-3 trial. The&#xD;
      trial will recruit 60 patients with small vessel disease, in two expert stroke centres&#xD;
      (Edinburgh and Nottingham) where there are suitable patients, expert stroke centres,&#xD;
      established trials infrastructures and neuroimaging and platelet testing expertise. The trial&#xD;
      will also advance methods to stratify patients by small vessel disease burden in routine&#xD;
      practise and data on intermediary mechanistic outcomes to assist in planning future trials&#xD;
      testing novel agents for either stroke or dementia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability proportion of patients able to tolerate the target dose</measure>
    <time_frame>8 weeks</time_frame>
    <description>proportion of patients able to tolerate the target dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - bleeding</measure>
    <time_frame>12 weeks</time_frame>
    <description>systemic or intracranial bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - recurrent stroke</measure>
    <time_frame>12 weeks</time_frame>
    <description>recurrent vascular events,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - death</measure>
    <time_frame>12 weeks</time_frame>
    <description>death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>reduction in blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - bleeding</measure>
    <time_frame>8 weeks</time_frame>
    <description>effect on platelet function assessed using p-selectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - cerebrovascular function</measure>
    <time_frame>8 weeks</time_frame>
    <description>effect on cerebrovascular reactivity assessed using carbon dioxide challenge in magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - systemic arterial stiffness</measure>
    <time_frame>8 weeks</time_frame>
    <description>effect on systemic large artery stiffness assessed with pulse wave velocity measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability Proportion of patients with headache that interferes with daily activities</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of patients with headache that interferes with daily activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability Proportion of patients with dizziness that interferes with daily activities</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of patients with dizziness that interferes with daily activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability Proportion of patients with nausea that interferes with daily activities</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of patients with nausea that interferes with daily activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability Proportion of patients with palpitations</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of patients with palpitations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability Proportion of patients with loose stools</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of patients with loose stools</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability Tablet count</measure>
    <time_frame>8 weeks</time_frame>
    <description>Tablet count</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Cerebral Small Vessel Diseases</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isosorbide mononitrate 25mg bd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cilostazol 100mg bd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isosorbide mononitrate 25mg bd and cilostazol 100mg bd start immediately</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Isosorbide mononitrate 25mg bd and cilostazol 100mg bd delayed start</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isosorbide mononitrate</intervention_name>
    <description>slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Isotard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilostazol</intervention_name>
    <description>phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>pletal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mild symptomatic ischaemic stroke in the past four years compatible with a clinical&#xD;
             lacunar stroke syndrome, with brain magnetic resonance imaging or computed tomography&#xD;
             scanning that is compatible with a symptomatic small subcortical (lacunar) infarct, or&#xD;
             if no recent relevant infarct is visible, that excluded other cause for symptoms&#xD;
&#xD;
          -  Age &gt; 35 years&#xD;
&#xD;
          -  Independent in activities of daily living (modified Rankin ≤2)&#xD;
&#xD;
          -  Able to give consent themselves&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other significant active neurological illness present since suffering stroke (eg&#xD;
             seizures, multiple sclerosis, brain tumour)&#xD;
&#xD;
          -  Age &lt; 35&#xD;
&#xD;
          -  Montreal Cognitive Assessment score &lt;26&#xD;
&#xD;
          -  Requiring assistance with activities of daily living (Modified Rankin ≥3)&#xD;
&#xD;
          -  Active cardiac disease (atrial fibrillation, myocardial infarction in past 6 months,&#xD;
             active angina, symptomatic cardiac failure)&#xD;
&#xD;
          -  Carotid stenosis &gt; 50% in the symptomatic artery territory requiring carotid&#xD;
             endarterectomy (prior and apparently successful carotid endarterectomy is not an&#xD;
             exclusion criterion)&#xD;
&#xD;
          -  Definite indication for, or definite contraindication to either trial drug&#xD;
&#xD;
          -  Unable to swallow&#xD;
&#xD;
          -  Bleeding tendency (platelets&lt;100, taking anticoagulant medication)&#xD;
&#xD;
          -  Unlikely to comply with trial medication&#xD;
&#xD;
          -  Planned surgery during the trial period&#xD;
&#xD;
          -  History of intracranial haemorrhage (subdural haematoma, subarachnoid haemorrhage,&#xD;
             intracerebral haemorrhage, but not asymptomatic haemorrhagic transformation of&#xD;
             infarction)&#xD;
&#xD;
          -  Other life threatening illness&#xD;
&#xD;
          -  History of drug overdose or attempted suicide or significant active mental illness&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  If recruited in Edinburgh and participating in cerebrovascular reactivity arm of&#xD;
             trial: active respiratory illness (such as moderate to severe asthma or chronic&#xD;
             obstructive airways disease), unable to tolerate magnetic resonance imaging or unable&#xD;
             to lie flat&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna M Wardlaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nottingham</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2RD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>June 19, 2015</study_first_submitted>
  <study_first_submitted_qc>June 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2015</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cerebral small vessel disease</keyword>
  <keyword>cerebrovascular reactivity</keyword>
  <keyword>cilostazol</keyword>
  <keyword>isosorbide mononitrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Small Vessel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

